БИОМЕДИЦИНСКИЙ ЖУРНАЛ МЕДЛАЙН.РУ
Содержание журнала

Архив

Редакция
Учредители

Федеральное государственное бюджетное учреждение науки
"Институт токсикологии Федерального медико-биологического агентства"


Федеральное государственное бюджетное учреждение науки
Институт теоретической и экспериментальной биофизики
Российской академии наук


ООО "ИЦ КОМКОН"

Адрес редакции и реквизиты

199406, Санкт-Петербург, ул.Гаванская, д. 49, корп.2

ISSN 1999-6314
Профилактическая медицина •

Том: 21
Статья: « 66 »
Страницы:. 819-828
Опубликована в журнале: 21 мая 2020 г.

English version

Токсичность антиретровирусных препаратов для лечения вич−инфекции

Улюкин И.М., Орлова Е.С., Шуклина А.А.

Военно-медицинская академия имени С. М. Кирова


Резюме
В обзоре рассмотрены основные токсические эффекты нуклеозидных ингибиторов обратной транскриптазы вируса иммунодефицита человека (ВИЧ), которые наиболее часто применяются в схемах антиретровирусной терапии ВИЧ−инфекции. Показана необходимость ведения постоянного мониторинга антиретровирусной терапии по разным направлениям, в том числе по изучению клинических и токсических последствий (так как не все события распознаются, и не обо всех распознанных событиях сообщается).


Ключевые слова
ВИЧ-инфекция, молодые люди, антиретровирусные препараты, токсичность, лечение, профилактика.



(статья в формате PDF. Для просмотра необходим Adobe Acrobat Reader)



открыть статью в новом окне

Список литературы

1. Федеральный научно-методический центр по профилактике и борьбе со СПИДом ФБУН Центрального НИИ эпидемиологии Роспотребнадзора. Справка «ВИЧ-инфекция в Российской Федерации в первом полугодии 2019 г.». - URL: http://aids-centr.perm.ru/images/4/hiv_in_russia/hiv_in_rf_30.06.2019.pdf. (дата обращения: 16.02.2020).


2. Bacchetti P., Gripshover B., Grunfeld C., Heymsfield S., McCreath H., Osmond D., Saag M., Scherzer R., Shlipak M., Tien P., Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIVinfection // J. Acquir. Immune Defic. Syndr. 2005. Vol.40, No. 2. P. 121-131. DOI: 10.1097/01.qai.0000182230.47819.aa


3. Bartlett K., Eaton S. Mitochondrial beta-oxidation // Eur. J. Biochem. 2004. Vol.271, No. 3. P. 462-469. DOI: 10.1046/j.1432-1033.2003.03947.x


4. Cherry C.L., Gahan M.E., McArthur J., Lewin S.R., Hoy J.F., Wesseling S.L. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat // J. Acquir. Immune Defic. Syndr. 2002. Vol. 30, No. 3. P, 271-277. DOI: 10.1097/00126334-200207010-00002


5. Coghlan M.E., Sommadossi J.P., Jhala N.C., Many W.J., Saag M.S., Johnson V.A. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases // Clin. Infect. Dis. 2001. Vol. 33, No. 11. P. 1914-1921. DOI: 10.1086/323783


6. Cossarizza A., Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria // AIDS. 2004. Vol. 18, No. 2. P. 137-151. DOI: 10.1097/00002030-200401230-00002


7. Dalakas M.C. Peripheral neuropathy and antiretroviral drugs // J. Peripher. Nerv. Syst. 2001. Vol. 6, No. 1. P. 14-20. DOI: 10.1046/j.1529-8027.2001.006001014.x


8. Dalakas M.C., Leon-Monzon M.E., Bernardini I., Gahl W.A., Jay C.A. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage // Ann. Neurol. 1994. Vol. 35. No. 4. P. 482-487. DOI: 10.1002/ana.410350418


9. Guidelines on the public health response to pretreatment HIV drug resistance. Geneva: World Health Organization, 2017. 84 p.


10. Hill A.L., Rosenbloom D.I., Fu F., Nowak M.A., Siliciano R.F. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 // Proc. Natl. Acad. Sci. USA. 2014. Vol. 111, No. 37. P. 13475-13480. DOI: 10.1073/pnas.1406663111


11. Kakuda T.N. Pharmacology of nucleoside and nucleotidereverse transcriptase inhibitor-induced mitochondrial toxicity // Clin.Ther. 2000. Vol. 22, No. 6. P. 685-708. DOI: 10.1016/S0149-2918(00)90004-3


12. Lewis W., Day B.J., Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective // Nat. Rev. Drug Discov. 2003. Vol. 2, No. 10. P. 812-822. DOI: 10.1038/nrd1201


13. McArthur J.C., Brew B.J., Nath A. Neurological complications of HIV infection // Lancet Neurol. 2005. Vol. 4, No. 9. P. 543-555. DOI: 10.1016/S1474-4422(05)70165-4


14. McComsey G.A.,Ward D.J., Hessenthaler S.M., SensionM.G., Shalit P., Lonergan J.T., Fisher R.L., Williams V.C., Hernandez J.E. Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL, ESS40010) Study Team. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin. Infect. Dis. 2004. Vol. 38, No. 2. P. 263-270. DOI: 10.1086/380790


15. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity // Clin. Ther. 2000. Vol. 22, No. 8. P. 911-936. DOI: 10.1016/S0149-2918(00)80064-8


16. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D., Investigators H.O.S. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection // New Engl. J. Med. 1998. Vol. 338, No. 13. P. 853-860. DOI: 10.1056/NEJM199803263381301


17. Shikuma C.M., Hu N., Milne C., Yost F., Waslien C., Shimizu S., Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy // AIDS. 2001. Vol. 15, No. 14. P 1801-1809. DOI: 10.1097/00002030-200109280-00009


18. Simpson D.M., Kitch D., Evans S.R., McArthur J.C., Asmuth D.M., Cohen B., Goodkin K., Gerschenson M., So Y., Marra C.M., Diaz-Arrastia R., Shriver S., Millar L., Clifford D.B., ACTG A547 Study Group. HIV neuropathy natural history cohort study: assessment measures and risk factors // Neurology. 2006. Vol. 66, No. 11. P. 1679-1687. DOI: 10.1212/01.wnl.0000218303.48113.5d


19. Simpson D.M., Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection // J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995. Vol. 9, No. 2. P. 153-161.


20. Wulff E.A., Wang A.K., Simpson D.M. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment // Drugs. 2000. Vol. 59, No. 6. P. 1251-1260. DOI: 10.2165/00003495-200059060-00005





References


1. Federal Scientific and Methodological Center for the Prevention and Control of AIDS of the Central Federal Research Institution of Epidemiology of Rospotrebnadzor. Enquiry «HIV infection in the Russian Federation in the first half of 2019». - URL: http://aids-centr.perm.ru/images/4/hiv_in_russia/hiv_in_rf_30.06.2019.pdf. (date of the application: 16.02.2020) [In Russian].


2. Bacchetti P., Gripshover B., Grunfeld C., Heymsfield S., McCreath H., Osmond D., Saag M., Scherzer R., Shlipak M., Tien P., Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIVinfection. J. Acquir. Immune Defic. Syndr. 2005. Vol.40, No. 2. P. 121-131. DOI: 10.1097/01.qai.0000182230.47819.aa


3. Bartlett K., Eaton S. Mitochondrial beta-oxidation. Eur. J. Biochem. 2004. Vol.271, No. 3. P. 462-469. DOI: 10.1046/j.1432-1033.2003.03947.x


4. Cherry C.L., Gahan M.E., McArthur J., Lewin S.R., Hoy J.F., Wesseling S.L. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J. Acquir. Immune Defic. Syndr. 2002. Vol. 30, No. 3. P, 271-277. DOI: 10.1097/00126334-200207010-00002


5. Coghlan M.E., Sommadossi J.P., Jhala N.C., Many W.J., Saag M.S., Johnson V.A. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin. Infect. Dis. 2001. Vol. 33, No. 11. P. 1914-1921. DOI: 10.1086/323783


6. Cossarizza A., Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS. 2004. Vol. 18, No. 2. P. 137-151. DOI: 10.1097/00002030-200401230-00002


7. Dalakas M.C. Peripheral neuropathy and antiretroviral drugs. J. Peripher. Nerv. Syst. 2001. Vol. 6, No. 1. P. 14-20. DOI: 10.1046/j.1529-8027.2001.006001014.x


8. Dalakas M.C., Leon-Monzon M.E., Bernardini I., Gahl W.A., Jay C.A. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann. Neurol. 1994. Vol. 35. No. 4. P. 482-487. DOI: 10.1002/ana.410350418


9. Guidelines on the public health response to pretreatment HIV drug resistance. Geneva: World Health Organization, 2017. 84 p.


10. Hill A.L., Rosenbloom D.I., Fu F., Nowak M.A., Siliciano R.F. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc. Natl. Acad. Sci. USA. 2014. Vol. 111, No. 37. P. 13475-13480. DOI: 10.1073/pnas.1406663111


11. Kakuda T.N. Pharmacology of nucleoside and nucleotidereverse transcriptase inhibitor-induced mitochondrial toxicity. Clin.Ther. 2000. Vol. 22, No. 6. P. 685-708. DOI: 10.1016/S0149-2918(00)90004-3


12. Lewis W., Day B.J., Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2003. Vol. 2, No. 10. P. 812-822. DOI: 10.1038/nrd1201


13. McArthur J.C., Brew B.J., Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005. Vol. 4, No. 9. P. 543-555. DOI: 10.1016/S1474-4422(05)70165-4


14. McComsey G.A.,Ward D.J., Hessenthaler S.M., SensionM.G., Shalit P., Lonergan J.T., Fisher R.L., Williams V.C., Hernandez J.E. Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL, ESS40010) Study Team. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin. Infect. Dis. 2004. Vol. 38, No. 2. P. 263-270. DOI: 10.1086/380790


15. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin. Ther. 2000. Vol. 22, No. 8. P. 911-936. DOI: 10.1016/S0149-2918(00)80064-8


16. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D., Investigators H.O.S. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl. J. Med. 1998. Vol. 338, No. 13. P. 853-860. DOI: 10.1056/NEJM199803263381301


17. Shikuma C.M., Hu N., Milne C., Yost F., Waslien C., Shimizu S., Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS. 2001. Vol. 15, No. 14. P 1801-1809. DOI: 10.1097/00002030-200109280-00009


18. Simpson D.M., Kitch D., Evans S.R., McArthur J.C., Asmuth D.M., Cohen B., Goodkin K., Gerschenson M., So Y., Marra C.M., Diaz-Arrastia R., Shriver S., Millar L., Clifford D.B., ACTG A547 Study Group. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology. 2006. Vol. 66, No. 11. P. 1679-1687. DOI: 10.1212/01.wnl.0000218303.48113.5d


19. Simpson D.M., Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995. Vol. 9, No. 2. P. 153-161.


20. Wulff E.A., Wang A.K., Simpson D.M. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs. 2000. Vol. 59, No. 6. P. 1251-1260. DOI: 10.2165/00003495-200059060-00005